tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DRMA Stock Latest News

Dermata says Australian Patent Office accepts Spongilla tech application
The FlyDermata says Australian Patent Office accepts Spongilla tech application
19d ago
DRMA
Dermata Therapeutics Presents Promising Phase 3 Trial Results
PremiumCompany Announcements
Dermata Therapeutics Presents Promising Phase 3 Trial Results
1M ago
8K
DRMA
Dermata Shifts Focus to Over-the-Counter Dermatology
PremiumCompany Announcements
Dermata Shifts Focus to Over-the-Counter Dermatology
1M ago
8K
DRMA
Dermata Therapeutics announces strategic pivot to OTC skin care treatments
PremiumThe Fly
Dermata Therapeutics announces strategic pivot to OTC skin care treatments
1M ago
DRMA
Dermata Therapeutics withdraws IND application for XYNGARI
PremiumThe Fly
Dermata Therapeutics withdraws IND application for XYNGARI
1M ago
DRMA
Dermata Therapeutics Regains Nasdaq Compliance by August 2025
PremiumCompany AnnouncementsDermata Therapeutics Regains Nasdaq Compliance by August 2025
2M ago
8K
DRMA
Dermata Therapeutics price target lowered to $10 from $30 at Maxim
Premium
The Fly
Dermata Therapeutics price target lowered to $10 from $30 at Maxim
2M ago
DRMA
Dermata Therapeutics Reports Positive Phase 3 Trial Results
Premium
Company Announcements
Dermata Therapeutics Reports Positive Phase 3 Trial Results
2M ago
8K
DRMA
Dermata Therapeutics Inc trading halted, news pending
PremiumThe Fly
Dermata Therapeutics Inc trading halted, news pending
3M ago
DRMA
Dermata Therapeutics Announces Reverse Stock Split
PremiumCompany Announcements
Dermata Therapeutics Announces Reverse Stock Split
3M ago
8K
DRMA
Dermata Therapeutics Holds Annual Stockholders Meeting
PremiumCompany Announcements
Dermata Therapeutics Holds Annual Stockholders Meeting
3M ago
8K
DRMA
Dermata Therapeutics receives notice of grant of Australian patent
PremiumThe Fly
Dermata Therapeutics receives notice of grant of Australian patent
3M ago
DRMA
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split
PremiumCompany AnnouncementsDermata Faces Nasdaq Delisting Risk, Plans Stock Split
4M ago
8K
DRMA
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial
Premium
Company Announcements
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial
5M ago
8K
DRMA
Dermata Therapeutics price target lowered to $3 from $6 at Maxim
Premium
The Fly
Dermata Therapeutics price target lowered to $3 from $6 at Maxim
5M ago
DRMA
Dermata Faces Nasdaq Delisting Risk Over Bid Price
PremiumCompany Announcements
Dermata Faces Nasdaq Delisting Risk Over Bid Price
5M ago
8K
DRMA
Dermata Reports Positive Phase 3 Trial Results
PremiumCompany Announcements
Dermata Reports Positive Phase 3 Trial Results
5M ago
8K
DRMA
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
PremiumThe Fly
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
5M ago
DRMA
Dermata Therapeutics sees cash runway into 1Q26
PremiumThe Fly
Dermata Therapeutics sees cash runway into 1Q26
5M ago
DRMA
Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position
PremiumRatingsOptimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position
6M ago
DRMA
Dermata Therapeutics files to sell 10.01M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 10.01M shares of common stock for holders
6M ago
DRMA
Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
Premium
The Fly
Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
6M ago
DRMA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >